312 related articles for article (PubMed ID: 10512365)
1. Unresponsiveness to glibenclamide during chronic treatment induced by reduction of ATP-sensitive K+ channel activity.
Kawaki J; Nagashima K; Tanaka J; Miki T; Miyazaki M; Gonoi T; Mitsuhashi N; Nakajima N; Iwanaga T; Yano H; Seino S
Diabetes; 1999 Oct; 48(10):2001-6. PubMed ID: 10512365
[TBL] [Abstract][Full Text] [Related]
2. The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide.
Sunaga Y; Gonoi T; Shibasaki T; Ichikawa K; Kusama H; Yano H; Seino S
Eur J Pharmacol; 2001 Nov; 431(1):119-25. PubMed ID: 11716850
[TBL] [Abstract][Full Text] [Related]
3. Characterization of low-affinity binding sites for glibenclamide on the Kir6.2 subunit of the beta-cell KATP channel.
Gros L; Virsolvy A; Salazar G; Bataille D; Blache P
Biochem Biophys Res Commun; 1999 Apr; 257(3):766-70. PubMed ID: 10208857
[TBL] [Abstract][Full Text] [Related]
4. Tissue specificity of sulfonylureas: studies on cloned cardiac and beta-cell K(ATP) channels.
Gribble FM; Tucker SJ; Seino S; Ashcroft FM
Diabetes; 1998 Sep; 47(9):1412-8. PubMed ID: 9726229
[TBL] [Abstract][Full Text] [Related]
5. Cooperative binding of ATP and MgADP in the sulfonylurea receptor is modulated by glibenclamide.
Ueda K; Komine J; Matsuo M; Seino S; Amachi T
Proc Natl Acad Sci U S A; 1999 Feb; 96(4):1268-72. PubMed ID: 9990013
[TBL] [Abstract][Full Text] [Related]
6. Glibenclamide binding to sulphonylurea receptor subtypes: dependence on adenine nucleotides.
Hambrock A; Löffler-Walz C; Quast U
Br J Pharmacol; 2002 Aug; 136(7):995-1004. PubMed ID: 12145099
[TBL] [Abstract][Full Text] [Related]
7. The molecular interaction of sulfonylureas with beta-cell ATP-sensitive K(+)-channels.
Kramer W; Müller G; Girbig F; Gutjahr U; Kowalewski S; Hartz D; Summ HD
Diabetes Res Clin Pract; 1995 Aug; 28 Suppl():S67-80. PubMed ID: 8529521
[TBL] [Abstract][Full Text] [Related]
8. A novel enhancer of insulinotrophic action by high glucose (JTT-608) stimulates insulin secretion from pancreatic beta-cells via a new cellular mechanism.
Itabashi N; Okada K; Muto S; Fujita N; Ohta T; Miyazaki Ji ; Asano Y; Saito T
J Pharmacol Exp Ther; 2001 Jun; 297(3):953-60. PubMed ID: 11356916
[TBL] [Abstract][Full Text] [Related]
9. Identification of the high-affinity tolbutamide site on the SUR1 subunit of the K(ATP) channel.
Ashfield R; Gribble FM; Ashcroft SJ; Ashcroft FM
Diabetes; 1999 Jun; 48(6):1341-7. PubMed ID: 10342826
[TBL] [Abstract][Full Text] [Related]
10. Kir6.2-dependent high-affinity repaglinide binding to beta-cell K(ATP) channels.
Hansen AM; Hansen JB; Carr RD; Ashcroft FM; Wahl P
Br J Pharmacol; 2005 Feb; 144(4):551-7. PubMed ID: 15678092
[TBL] [Abstract][Full Text] [Related]
11. Testing the bipartite model of the sulfonylurea receptor binding site: binding of A-, B-, and A + B-site ligands.
Winkler M; Stephan D; Bieger S; Kühner P; Wolff F; Quast U
J Pharmacol Exp Ther; 2007 Aug; 322(2):701-8. PubMed ID: 17495126
[TBL] [Abstract][Full Text] [Related]
12. Metabolic inhibition impairs ATP-sensitive K+ channel block by sulfonylurea in pancreatic beta-cells.
Mukai E; Ishida H; Kato S; Tsuura Y; Fujimoto S; Ishida-Takahashi A; Horie M; Tsuda K; Seino Y
Am J Physiol; 1998 Jan; 274(1):E38-44. PubMed ID: 9458745
[TBL] [Abstract][Full Text] [Related]
13. Selectivity of repaglinide and glibenclamide for the pancreatic over the cardiovascular K(ATP) channels.
Stephan D; Winkler M; Kühner P; Russ U; Quast U
Diabetologia; 2006 Sep; 49(9):2039-48. PubMed ID: 16865362
[TBL] [Abstract][Full Text] [Related]
14. Sulphonylurea receptor 2B and Kir6.1 form a sulphonylurea-sensitive but ATP-insensitive K+ channel.
Yamada M; Isomoto S; Matsumoto S; Kondo C; Shindo T; Horio Y; Kurachi Y
J Physiol; 1997 Mar; 499 ( Pt 3)(Pt 3):715-20. PubMed ID: 9130167
[TBL] [Abstract][Full Text] [Related]
15. Interaction of K(ATP) channel modulators with sulfonylurea receptor SUR2B: implication for tetramer formation and allosteric coupling of subunits.
Löffler-Walz C; Hambrock A; Quast U
Mol Pharmacol; 2002 Feb; 61(2):407-14. PubMed ID: 11809866
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a mutant sulfonylurea receptor SUR2B with high affinity for sulfonylureas and openers: differences in the coupling to Kir6.x subtypes.
Hambrock A; Löffler-Walz C; Russ U; Lange U; Quast U
Mol Pharmacol; 2001 Jul; 60(1):190-9. PubMed ID: 11408614
[TBL] [Abstract][Full Text] [Related]
17. Structural requirements of sulphonylureas and analogues for interaction with sulphonylurea receptor subtypes.
Meyer M; Chudziak F; Schwanstecher C; Schwanstecher M; Panten U
Br J Pharmacol; 1999 Sep; 128(1):27-34. PubMed ID: 10498831
[TBL] [Abstract][Full Text] [Related]
18. Interaction of the sulfonylthiourea HMR 1833 with sulfonylurea receptors and recombinant ATP-sensitive K(+) channels: comparison with glibenclamide.
Russ U; Lange U; Löffler-Walz C; Hambrock A; Quast U
J Pharmacol Exp Ther; 2001 Dec; 299(3):1049-55. PubMed ID: 11714894
[TBL] [Abstract][Full Text] [Related]
19. Control of insulin secretion by sulfonylureas, meglitinide and diazoxide in relation to their binding to the sulfonylurea receptor in pancreatic islets.
Panten U; Burgfeld J; Goerke F; Rennicke M; Schwanstecher M; Wallasch A; Zünkler BJ; Lenzen S
Biochem Pharmacol; 1989 Apr; 38(8):1217-29. PubMed ID: 2650685
[TBL] [Abstract][Full Text] [Related]
20. Molecular structure of the glibenclamide binding site of the beta-cell K(ATP) channel.
Mikhailov MV; Mikhailova EA; Ashcroft SJ
FEBS Lett; 2001 Jun; 499(1-2):154-60. PubMed ID: 11418131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
